During the past decade, Melanoma Institute Australia conducted 22 clinical trials. In the 10-year time frame, 22 clinical trials started and 9 clinical trials were completed, i.e. on average, 40.9% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 6 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Melanoma Institute Australia" #1 sponsor was "Hoffmann-La Roche" with 7 trials, followed by "Melanoma and Skin Cancer Trials Limited" with 5 trials sponsored, "Melanoma Institute Australia" with 4 trials sponsored, "Pfizer" with 4 trials sponsored and "Bristol-Myers Squibb" with 4 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Melanoma Institute Australia" #1 collaborator was "Merck Sharp & Dohme LLC" with 5 trials as a collaborator, "Bristol-Myers Squibb" with 2 trials as a collaborator, "Melanoma Institute Australia" with 2 trials as a collaborator, "Melanoma and Skin Cancer Trials Limited" with 2 trials as a collaborator and "Trans Tasman Radiation Oncology Group" with 2 trials as a collaborator. Other collaborators include 15 different institutions and companies that were collaborators in the rest 25 trials.

According to Clinical.Site data, the most researched conditions in "Melanoma Institute Australia" are "Melanoma" (11 trials), "Malignant Melanoma" (3 trials), "Brain Metastases" (2 trials), "Metastatic Melanoma" (2 trials) and "Skin Cancer" (2 trials). Many other conditions were trialed in "Melanoma Institute Australia" in a lesser frequency.

Most popular intervention types in "Melanoma Institute Australia" are "Drug" (23 trials), "Biological" (5 trials), "Procedure" (4 trials), "Radiation" (3 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Nivolumab" (6 trials), "Pembrolizumab" (5 trials), "Ipilimumab" (4 trials), "Placebo" (4 trials) and "Vemurafenib" (3 trials). Other intervention names were less common.

The vast majority of trials in "Melanoma Institute Australia" are 32 trials for "All" genders.

Currently, there are NaN active trials in "Melanoma Institute Australia". undefined are not yet recruiting, 6 are recruiting, 12 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Melanoma Institute Australia, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Melanoma Institute Australia, 9 "Phase 1" clinical trials were conducted, 15 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 4 trials that are defined as “Not Applicable".